NVAC charter, GLP-1 telehealth: July 2026

STAT News' morning-rounds newsletter for 20 July 2026 covered five health-policy developments in a single edition: a rewritten charter for a federal vaccine advisory committee, GLP-1 telehealth prescribing allegations, a Medicare reimbursement change buried in a 1,592-page document, England's SMA newborn-screening expansion, and a new naloxone access analysis. Three of the five have direct relevance to readers following^[1] GLP-1 drugs and their regulatory environment.

The NVAC got a new charter on 7 July 2026

The National Vaccine Advisory Committee (NVAC) received a new charter dated 7 July, according to Helen Branswell's reporting. NVAC advises the HHS Secretary on vaccine policy and has historically drawn its members from vaccine researchers, physicians, and public-health officials^[1].

The updated charter makes two structural changes. First, it broadens NVAC's mandate beyond vaccines to include disease-prevention tools for people unwilling or unable to be vaccinated, explicitly naming dietary supplements and 'repurposed use' of FDA-approved drugs. Second, it limits how many academics with industry-funded vaccine research can serve on the committee, and increases the share of public members. Branswell noted the change came despite reported White House directives to hold off on vaccine-policy moves before midterm elections^[1].

NVAC advises; it does not set schedules. Vaccine recommendations remain with the CDC's Advisory Committee on Immunization Practices. Any downstream effect on clinical guidance would require a separate step. What the NVAC change does is shift the composition of the table where federal vaccine strategy gets discussed, and expands the category of interventions that table is formally authorised to consider. For the incretin-drug regulatory picture, see the tirzepatide regulation overview.

LifeMD faces GLP-1 telehealth prescribing allegations

Elaine Chen's story in the same roundup reported allegations against LifeMD, a telehealth platform promoted by Novo Nordisk as a prescribing channel for weight-loss GLP-1 drugs. Five former employees and two separate lawsuits describe internal pressure on clinicians to approve prescriptions faster and with less screening than a standard clinical assessment would involve^[1].

A former executive, identified as Brad Roberts, claimed the chief medical officer prescribed him six different GLP-1 drugs in sequence, a claim that implies a pace inconsistent with standard of care. CEO Justin Schreiber denied the characterisation to STAT: 'Our objective has not been to run a pill mill.'^[1] No regulatory enforcement action by the FDA or a state medical board has been taken against LifeMD as of this writing. The allegations are civil and employment-related, not regulatory findings.

The platform-prescribing concern is separate from the safety profile of the drugs themselves. Semaglutide and tirzepatide carry well-characterised adverse-event profiles and specific contraindications, including personal or family history of medullary thyroid carcinoma and multiple endocrine neoplasia type 2. A prescribing process that is screening-light creates conditions for those contraindications to go undetected. For country-specific regulatory rules on GLP-1 prescribing, see thesemaglutide regulation pages.

Medicare proposes 19% more for tobacco cessation counselling

A proposed 19% reimbursement increase for tobacco cessation counselling sits on page 783 of CMS's 1,592-page calendar-year 2027 Medicare physician fee schedule proposal, per Sarah Todd's reporting. The change targets the counselling billing code, not prescription pharmacotherapy^[1].

Ned Sharpless, former director of the National Cancer Institute, was quoted endorsing the move: 'We have something to offer these patients.' The US Preventive Services Task Force gives tobacco cessation interventions a Grade A recommendation, its highest rating, for all adults^[2]. Smoking causes more than 480,000 deaths per year in the United States. A reimbursement floor that is financially uncompetitive with procedural codes creates a disincentive to prioritise cessation conversations in primary care.^[1]

The proposed increase is part of a rule that goes through a comment period before it becomes final. It does not change coverage of prescription cessation medications, which are handled under separate formulary rules.

Two more items from the same edition

England moved its SMA newborn-screening programme from pilot to full coverage by next year. All 50 US states and most of Europe had already adopted spinal muscular atrophy screening at birth. England was the notable holdout among peer health systems^[1].

A JAMA Network Open analysis of more than 1,100 US pharmacies found that 61% offered same-day naloxone availability, 73% kept it behind the counter, and the average cost was $52. Availability correlated with the racial demographics of the surrounding area and with chain pharmacy status^[1]. Communities with fewer chain pharmacies and lower incomes face the combined barrier of reduced access and a $52 out-of-pocket cost.

What the pattern adds up to

The NVAC charter change, the LifeMD allegations, and the tobacco-counselling reimbursement proposal each turn on the same structural question: who is at the table, what counts as adequate clinical process, and how payment shapes clinical behaviour. These are the same forces shaping whether semaglutide and tirzepatide prescribing normalises in primary care or stays concentrated in specialist and telehealth channels. Governance decisions made this month will set the conditions for prescribing practice in 2027 and beyond.^[1]

This article is for informational purposes only. Nothing here constitutes medical advice. Before starting, adjusting, or stopping any prescription medication, including semaglutide or tirzepatide, speak with a licensed healthcare provider who knows your full clinical history.